BioCentury This Week

BioCentury

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

All episodes

Best episodes

Seasons

Top 10 BioCentury This Week Episodes

Goodpods has curated a list of the 10 best BioCentury This Week episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to BioCentury This Week for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite BioCentury This Week episode by adding your comments to the episode page.

Ep. 33 - ASH Preview & Long Shot Drug Pricing Rule

BioCentury This Week

11/24/20 • 21 min

Reach us by sending a text

Ep. 13 - Nuances of NASH, COVID Vaccines and Real-World Data

BioCentury This Week

07/06/20 • 15 min

Reach us by sending a text

Ep. 6 - New Faces for COVID-19’s Next Phase, ASCO’s Hot Topics

BioCentury This Week

05/19/20 • 18 min

Reach us by sending a text

Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights

BioCentury This Week

11/22/21 • 23 min

Reach us by sending a text

Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago

BioCentury This Week

06/12/25 • 31 min

With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements in innovation.
One potential bright spot: Pharma, which is turning to academia to access first-in-class innovation. But many in pharma complain it is difficult to work with academia.
On a special Grand Rounds edition of the BioCentury This Week podcast, BioCentury analysts and special guests discuss a new way of thinking and a new era of collaboration between academia and industry.
View full story: https://www.biocentury.com/article/656177
#biotech #biopharma #pharma #lifescience #Discovery #Translation #BioCenturyGrandRounds
00:00 - Introduction
02:38 - Key Findings
07:42 - Collaboration and Opportunities
25:52 - BioCentury Grand Rounds Europe
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text

Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans

BioCentury This Week

06/10/25 • 35 min

Translational trends at this year’s ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the findings from Executive Director of Biopharma Intelligence Lauren Martz’s deep dive into first-in-human studies at the American Society of Clinical Oncology meeting, including how immunocytokines, solid tumor CAR Ts and Chinese innovation are thriving in early trials.
The analysts also examine the signs of strain and resilience in biotech’s crossover investors, as well as FDA’s plans for revamping rare disease regulation. This episode of BioCentury This Week was sponsored by ICON Biotech.
View full story: https://www.biocentury.com/article/656139
#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment
00:01 - Sponsor Message: ICON Biotech
02:11 - ASCO’s First-in-Human Trials
12:46 - Crossover Investor Health Check
22:54 - FDA's Rare Disease Plans
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].